Skip to main content

Table 1 Clinicopathological characteristics of 80 invasive breast cancer patients

From: Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome

Characteristics pBRE I-II Survivors ≥8years (n = 21) pBRE III Survivors ≥8years (n = 19) pBRE I-II Survivors < 8 years (n = 20) pBRE III Survivors <8 years (n = 20)
Mean age (y) 58 (39–72) 52 (27–7) 55 (39–71) 53 (33–72)
Histologic type     
Ductal 15 (71) 18 (95) 15 (75) 16 (80)
Lobular 2 (10) 1 (5) 4 (20) 3 (15)
Ductal + lobular 0 (0) 0 (0) 1 (5) 0 (0)
Other 3 (14) 0 (0) 0 (0) 1 (5)
Not available 1 (5) 0 (0) 0 (0) 0 (0)
Pathologic tumor size (mm)     
pT1 (0–20) 2 (9) 6 (32) 3 (15) 5 (25)
pT2 (>20-50) 18 (86) 9 (47) 16 (80) 13 (65)
pT3 (>50) 1 (5) 4 (21) 1 (5) 2 (10)
pT4 0 (0) 0 (0) 0 (0) 0 (0)
BRE grade     
I-II 21 (100)   20 (100)  
III   19 (100)   20 (100)
No. of axillary lymph nodes     
0 7 (33) 7 (37) 7 (35) 7 (35)
1-3 5 (24) 7 (37) 6 (30) 6 (30)
≥4 9 (43) 5 (26) 7 (35) 7 (35)
Surgery     
Lumpectomy 9 (43) 6 (32) 9 (45) 6 (30)
Mastectomy 12 (57) 13 (68) 11 (55) 14 (70)
ER/PR status     
Negative 11 (52) 8 (42) 13 (65) 7 (35)
Positive 9 (43) 11 (58) 7 (35) 13 (65)
Not available 1 (5)    
HER2/ neu status     
Positive 7 (33) 8 (42) 8 (40) 3 (15)
Negative 11 (52) 10 (53) 11 (55) 9 (45)
Not available 3 (15) 1 (5) 1 (5) 8 (40)
  1. (N) = No. of patients (%).
  2. BRE, Bloom, Richardson, Elston/Ellis; ER/PR: Estrogen/progesterone receptor.